Clinical Trial Update: MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a MEK inhibitor in combination with a PD-L1 inhibitor for locally advanced or metastatic soft tissue sarcoma has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• MEK inhibitor (unspecified) (MEK inhibitor)
• PD-L1 inhibitor (unspecified)

Snippet

Sponsor: Centre Leon Berard | Conditions: Sarcoma,Soft Tissue | Phase 1, Phase 2 | Status: COMPLETED